Products for Research Use Only
RegisterLogin

SB-273005

CAT: 0804-HY-19307-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19307-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with Ki values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. [1][2][3][4][5].
CAS Number
205678-31-5
UNSPSC
12352005
Target
Integrin; Interleukin Related
Type
Reference compound
Related Pathways
Cytoskeleton; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sb-273005.html
Concentration
10mM
Purity
99.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C[C@H]1C(N(CC(F)(F)F)CC2=CC(OCCC3=NC(NC)=CC=C3)=CC=C2C1)=O
Molecular Formula
C22H24F3N3O4
Molecular Weight
451.44
References & Citations
[1]Badger AM, et al. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. 2001 Jan;44 (1) :128-37. |[2]Rehm S, et al. Novel vascular lesions in mice given a non-peptide vitronectin receptor antagonist. Toxicol Pathol. 2007 Dec;35 (7) :958-71. |[3]Parker SJ, et al. Proteomics reveals Rictor as a noncanonical TGF-β signaling target during aneurysm progression in Marfan mice. Am J Physiol Heart Circ Physiol. 2018 Nov 1;315 (5) :H1112-H1126.|[4]Wang S, et al. SB-273005, an antagonist of αvβ3 integrin, reduces the production of Th2 cells and cytokine IL-10 in pregnant mice. Exp Ther Med. 2014 Jun;7 (6) :1677-1682. |[5]Hoffman SJ, et al. Rapid inhibition of thyroxine-induced bone resorption in the rat by an orally active vitronectin receptor antagonist. J Pharmacol Exp Ther. 2002 Jul;302 (1) :205-11.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
IL-10; αvβ3; αvβ5

Related Products

CatalogName
HY-135439SB-203186
HY-125082SB 204144
HY-100307SB 247464
HY-13521-01SB-505124
HY-10666SB-436811
HY-10847SB-277011
HY-10295-01SB 202190
HY-70068-01SB-408124
HY-15105-01SB-423562
HY-13052SB-737050A

Alternative Products

CatalogName
GTR19153626-01SB-269970, SB 269970
217783SB-277011-A Dihydrochloride (SB277011A, SB 277011A, Dopamine D3 Receptor Antagonist, SB-277011-A, SB-277011A)
366911-01SB 216763 (SB216763, SB-216763, SCHEMBL30251)
BA5664-5SB-649868
BA8268-10SB-435495
B6710-10SB 218795
BA5318-1SB-209670
B8200-5SB 225002
B6713-10SB 221284
B1281-5.1SB-334867

Popular Products